Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Physician and Sportsmedicine 2014-May

Pregabalin reduces opioid consumption and improves outcome in chronic pain patients undergoing total knee arthroplasty.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
Hind Sawan
Antonia F Chen
Eugene R Viscusi
Javad Parvizi
William J Hozack

Märksõnad

Abstraktne

BACKGROUND

Recently, multimodal pain control has been used to manage postoperative pain in patients undergoing total knee arthroplasty (TKA). This approach combines numerous modalities, such as opioids, nonsteroidal anti-inflammatory drugs, local anesthetics, and acetaminophen, in an effort to reduce overall opioid consumption and also to provide better pain control. Gabapentinoids are a class of drugs that have been used as part of multimodal approach, and may be effective in patients who are previous users of chronic pain medication. The hypothesis of this study was that the addition of pregabalin reduces opioid consumption and/or improves pain after TKA, even in patients who are previous users of chronic pain medications.

METHODS

Using a prospectively collected database, 262 consecutive patients undergoing primary TKA between December 2011 and April 2012 were identified who received multimodal analgesia after surgery that included pregabalin. Using the same database, these patients were compared with 268 patients undergoing TKA from January to December 2010 who also received multimodal analgesia but were not given pregabalin. The clinical records of these patients were reviewed in detail to determine the incidence and nature of postoperative complications, opioid consumption, and visual analog scale (VAS) pain scores.

RESULTS

The incidence of respiratory, renal, and hemodynamic complications was significantly lower in the patients who received pregabalin. Gastrointestinal complications, which included nausea, were not significantly different between the groups. Patients receiving pregabalin had a lower average opioid consumption, and their minimum and maximum levels of opioid consumption were also reduced. Previous users of chronic pain medications had higher VAS scores but the same opioid consumption compared with those who were not previous users of chronic pain medications. No difference was seen in the maximum VAS scores between patients who received pregabalin and those who did not.

CONCLUSIONS

Pregabalin in the context of multimodal pain management may be associated with reduced opioid consumption and other medical complications in patients undergoing TKA, including previous users of chronic pain medications.

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge